Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Oral Premalignant Lesions With 5-ALA PDT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* At least one grossly visible premalignant lesion (i.e. leukoplakia or erythroplakia) in the oral cavity or oropharynx, with a confirmed diagnosis of leukoplakia with or without dysplasia,measuring ≥ 10 mm in diameter.~* Informed of alternative treatment methods including watchful waiting, laser ablation, or surgical resection.~* Eligible for long-term follow-up for at least one year and be able to tolerate biopsies.~* Subject has signed an informed consent.~* Subject is between the ages of 18 - 80 years of age.~* Male or Female~* Zubrod performance status of 0 or 1 at screening. See Appendix A~Exclusion Criteria:~* Known sensitivity to porphyrins or photoactive medications - See Appendix B~* Invasive carcinoma of the lesion as demonstrated by biopsy.~* Subjects with inherited or acquired blood clotting defects~* Women who are breast feeding, have a positive (+) urine pregnancy test, or refuse to use 2 effective means of contraception during drug exposure and up to 48 hours after.~* Subjects with porphyria~* Life expectancy less than 12 months~* Inability or unwillingness of subject to give written informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 light dose escalation (Type: EXPERIMENTAL): During Phase I, to determine the maximum tolerated energy density of the Pulse Dye Laser operated at 585 nm with a pulse time of 1.5 ms (PDL-585), when used in combination with 5-aminolevulinic acid (5-ALA) applied topically to the premalignant lesion.~The maximum tolerated energy density will be called the Maximum Tolerated Dose (MTD). Procedure: Fluorescence Diagnosis Imaging Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 6, 7 and 8 J/cm2.
- Phase 2 - Treatment efficacy of PDT (Type: EXPERIMENTAL): Procedure: Fluorescence Diagnosis Imaging~Interventions: Application of 5-ALA to lesion followed by activation with high power 585 nm pulsed dye laser (PDL-585, ScleroPLUS laser) at 8 J/cm2.

Based on this trial design, predict the completion outcome and termination type (if applicable).